Advertisement
Screener

LEXICON PHARMACEUTICALS, INC. (LXRX) Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted

2.1 / 5 stars · 33/79 Roast Me

LEXICON PHARMACEUTICALS, INC. Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted

LEXICON PHARMACEUTICALS, INC. (LXRX) reported Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted of -$23.12 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-09.

Discontinued › Notes › Earnings Per Share › Undistributed Earnings (Loss) Available to Common Shareholders, Diluted

us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted · last filed 2021-11-09

  • LEXICON PHARMACEUTICALS, INC. undistributed earnings (loss) allocated to participating securities, diluted for the quarter ending 2021-09-30 was -$23.12M, a 127.57% decline year-over-year.
  • LEXICON PHARMACEUTICALS, INC. undistributed earnings (loss) allocated to participating securities, diluted for the quarter ending 2020-09-30 was $83.86M, a 63.12% decline year-over-year.
  • LEXICON PHARMACEUTICALS, INC. undistributed earnings (loss) allocated to participating securities, diluted for the quarter ending 2019-09-30 was $227.36M.
  • LEXICON PHARMACEUTICALS, INC. undistributed earnings (loss) allocated to participating securities, diluted for the quarter ending 2018-09-30 was -$27.40M.
Period endUndistributed Earnings (Loss) Allocated to Participating Securities, Diluted 3 monthUndistributed Earnings (Loss) Allocated to Participating Securities, Diluted 9 month
2021-09-30-$23.12M
10-Q · filed 2021-11-09
-$62.15M
10-Q · filed 2021-11-09
2020-09-30$83.86M
10-Q · filed 2021-11-09
-$53.08M
10-Q · filed 2021-11-09
2019-09-30$227.36M
10-Q · filed 2020-10-30
$185.06M
10-Q · filed 2020-10-30
2018-09-30-$27.40M
10-Q · filed 2019-11-07
-$103.77M
10-Q · filed 2019-11-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74
GERON CORP (GERN)United States$0.803B-12.14
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
Olema Pharmaceuticals, Inc. (OLMA)United States$0.790B-5.35
ARDELYX, INC. (ARDX)United States$0.857B-22.86
Wave Life Sciences, Inc. (WVE)$0.780B-5.56
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78